Findings GLP-1 receptor agonists and dual incretin agonists exert their therapeutic effects through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of glucagon release, appetite reduction, and slowing of gastric emptying
The initiatives specifically target those at high risk of major adverse cardiovascular events, with a policy shift potentially expanding access for a subset of Medicaid patients
This hormone tells your brain when you feel full after eating
A.OberleyM
Even without formal certification, structured CME on GLP-1 pharmacology, patient selection criteria, and safety monitoring is essential before you write your first prescription
I know that we'll get into talking about a lot of the neurological benefits of being on these drugs, but let's talk about how they work, how they came about, and then for you may be giving us some of your least favorite false narratives that are surrounding these right now